411 related articles for article (PubMed ID: 30004857)
1. Avelumab: A Novel Anti-PD-L1 Agent in the Treatment of Merkel Cell Carcinoma and Urothelial Cell Carcinoma.
Teets A; Pham L; Tran EL; Hochmuth L; Deshmukh R
Crit Rev Immunol; 2018; 38(3):159-206. PubMed ID: 30004857
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 inhibition with avelumab for metastatic Merkel cell carcinoma.
Gaiser MR; Bongiorno M; Brownell I
Expert Rev Clin Pharmacol; 2018 Apr; 11(4):345-359. PubMed ID: 29478343
[TBL] [Abstract][Full Text] [Related]
3. Avelumab: a new standard for treating metastatic Merkel cell carcinoma.
Baker M; Cordes L; Brownell I
Expert Rev Anticancer Ther; 2018 Apr; 18(4):319-326. PubMed ID: 29482384
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 blockade with avelumab: A new paradigm for treating Merkel cell carcinoma.
Barkdull S; Brownell I
Cancer Biol Ther; 2017 Dec; 18(12):937-939. PubMed ID: 29172995
[TBL] [Abstract][Full Text] [Related]
5. Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial.
D'Angelo SP; Bhatia S; Brohl AS; Hamid O; Mehnert JM; Terheyden P; Shih KC; Brownell I; Lebbé C; Lewis KD; Linette GP; Milella M; Georges S; Shah P; Ellers-Lenz B; Bajars M; Güzel G; Nghiem PT
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32414862
[TBL] [Abstract][Full Text] [Related]
6. Avelumab: A Review in Metastatic Merkel Cell Carcinoma.
Shirley M
Target Oncol; 2018 Jun; 13(3):409-416. PubMed ID: 29799096
[TBL] [Abstract][Full Text] [Related]
7. Product review: avelumab, an anti-PD-L1 antibody.
Collins JM; Gulley JL
Hum Vaccin Immunother; 2019; 15(4):891-908. PubMed ID: 30481100
[TBL] [Abstract][Full Text] [Related]
8. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial.
Patel MR; Ellerton J; Infante JR; Agrawal M; Gordon M; Aljumaily R; Britten CD; Dirix L; Lee KW; Taylor M; Schöffski P; Wang D; Ravaud A; Gelb AB; Xiong J; Rosen G; Gulley JL; Apolo AB
Lancet Oncol; 2018 Jan; 19(1):51-64. PubMed ID: 29217288
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim Analysis of a Clinical Trial.
D'Angelo SP; Russell J; Lebbé C; Chmielowski B; Gambichler T; Grob JJ; Kiecker F; Rabinowits G; Terheyden P; Zwiener I; Bajars M; Hennessy M; Kaufman HL
JAMA Oncol; 2018 Sep; 4(9):e180077. PubMed ID: 29566106
[TBL] [Abstract][Full Text] [Related]
10. [Immune checkpoint inhibition in Merkel cell carcinoma].
Terheyden P; Mohr A; Langan EA
Hautarzt; 2019 Sep; 70(9):684-690. PubMed ID: 31468071
[TBL] [Abstract][Full Text] [Related]
11. Which place for avelumab in the management of urothelial carcinoma?
Larroquette M; Gross-Goupil M; Daste A; Robert G; Ravaud A; Domblides C
Expert Opin Biol Ther; 2019 Sep; 19(9):863-870. PubMed ID: 31286802
[No Abstract] [Full Text] [Related]
12. Immunotherapy for Merkel Cell Carcinoma.
Nagase K; Narisawa Y
Curr Treat Options Oncol; 2018 Sep; 19(11):57. PubMed ID: 30238195
[TBL] [Abstract][Full Text] [Related]
13. Avelumab and other recent advances in Merkel cell carcinoma.
Bommareddy PK; Kaufman HL
Future Oncol; 2017 Dec; 13(30):2771-2783. PubMed ID: 28976209
[TBL] [Abstract][Full Text] [Related]
14. Immune Checkpoint Inhibitors and Beyond: An Overview of Immune-Based Therapies in Merkel Cell Carcinoma.
Samimi M
Am J Clin Dermatol; 2019 Jun; 20(3):391-407. PubMed ID: 30784027
[TBL] [Abstract][Full Text] [Related]
15. Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial.
Kaufman HL; Russell JS; Hamid O; Bhatia S; Terheyden P; D'Angelo SP; Shih KC; Lebbé C; Milella M; Brownell I; Lewis KD; Lorch JH; von Heydebreck A; Hennessy M; Nghiem P
J Immunother Cancer; 2018 Jan; 6(1):7. PubMed ID: 29347993
[TBL] [Abstract][Full Text] [Related]
16. Avelumab: A Review of Its Application in Metastatic Merkel Cell Carcinoma.
Joseph J; Zobniw C; Davis J; Anderson J; Trinh VA
Ann Pharmacother; 2018 Sep; 52(9):928-935. PubMed ID: 29616562
[TBL] [Abstract][Full Text] [Related]
17. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial.
Kaufman HL; Russell J; Hamid O; Bhatia S; Terheyden P; D'Angelo SP; Shih KC; Lebbé C; Linette GP; Milella M; Brownell I; Lewis KD; Lorch JH; Chin K; Mahnke L; von Heydebreck A; Cuillerot JM; Nghiem P
Lancet Oncol; 2016 Oct; 17(10):1374-1385. PubMed ID: 27592805
[TBL] [Abstract][Full Text] [Related]
18. Avelumab for the treatment of metastatic Merkel cell carcinoma.
Cordes LM; Gulley JL
Drugs Today (Barc); 2017 Jul; 53(7):377-383. PubMed ID: 28837181
[TBL] [Abstract][Full Text] [Related]
19. Diffuse lichen planus-like keratoses and clinical pseudo-progression associated with avelumab treatment for Merkel cell carcinoma, a case report.
Cardis MA; Jiang H; Strauss J; Gulley JL; Brownell I
BMC Cancer; 2019 Jun; 19(1):539. PubMed ID: 31164102
[TBL] [Abstract][Full Text] [Related]
20. First-line avelumab treatment in patients with metastatic Merkel cell carcinoma: 4-year follow-up from part B of the JAVELIN Merkel 200 study.
D'Angelo SP; Lebbé C; Mortier L; Brohl AS; Fazio N; Grob JJ; Prinzi N; Hanna GJ; Hassel JC; Kiecker F; von Heydebreck A; Güzel G; Nghiem P
ESMO Open; 2024 May; 9(5):103461. PubMed ID: 38744102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
